Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Morphotek, Centocor Enter Antibody Licensing Deal | Contract Pharma

What are you searching for?

Sign in
Breaking News

Morphotek, Centocor Enter Antibody Licensing Deal

Morphotek, Inc. has entered into a license agreement with Centocor Ortho Biotech for the development and commercialization of an antibody targeting solid tumors. Financial terms were not disclosed.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Morphotek, Inc. has entered into a license agreement with Centocor Ortho Biotech for the development and commercialization of an antibody targeting solid tumors. Financial terms were not disclosed.

Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Preclinical studies conducted by Centocor have shown that the relevant antigen is over-expressed in many solid tumors.

“We are delighted to conclude this license agreement with Centocor Ortho Biotech as we are committed to bringing healthcare solutions to cancer patients, especially for areas of unmet medical need,” said Philip Sass, Ph.D., chief operating officer of Morphotek. “Morphotek is well positioned to apply its technologies, knowledge and expertise in monoclonal antibody development for the development and commercialization of this antibody. The preclinical data package for this antibody have shown anti-cancer effects and we look forward to validating these in human trials.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters